
Opinion|Videos|September 26, 2024
Key Highlights From NATALEE at ESMO 2024
Panelists discuss how the NATALEE study at ESMO 2024 presented updates on primary, secondary, and exploratory end points for evaluating a new cancer treatment.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5











































